Suggested guidelines for the use of tacrolimus in cardiac transplant recipients.
Taylor
D O
DO
Department of Medicine, Division of Cardiology, University of Utah, Salt Lake City, Utah 84132, USA.
Barr
M L
ML
Meiser
B M
BM
Pham
S M
SM
Mentzer
R M
RM
Gass
A L
AL
D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004344:Drug Incompatibility; D004347:Drug Interactions; D016903:Drug Monitoring / Q000592:standards; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy; D016027:Heart Transplantation / Q000276:immunology* / Q000592:standards*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D016559:Tacrolimus